GSK is submitting data to the FDA regarding potential expansion of its drug indications.
2 reports, 2 independent
Updated Thu 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK is submitting data to the FDA regarding potential expansion of its drug indications.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Also in this story
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.
The entities involved
- FDA
-
GSK
British multinational pharmaceutical and biotechnology company
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA reviewed protocol amendment and interim safety data for a company's product.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.